CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-06 | Hallett David Chief Scientific Officer | Grant or award | +24,254 | 1,120,459 | ||
| 2026-02-06 | Hallett David Chief Scientific Officer | Shares withheld for taxes | −11,400 | $3.98 | $45K | 1,109,059 |
| 2026-02-06 | Gibson Christopher Director | Grant or award 10b5-1 | +30,346 | 944,185 | ||
| 2026-02-06 | Gibson Christopher Director | Shares withheld for taxes 10b5-1 | −10,364 | $3.56 | $37K | 933,821 |
| 2026-02-04 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 953,839 | ||
| 2026-02-04 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $4.12 | $165K | 913,839 |
| 2026-02-04 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,583,334 | ||
| 2026-02-03 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.20 | $924K | 6,429,863 |
| 2026-01-20 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 953,839 | ||
| 2026-01-20 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $4.47 | $179K | 913,839 |
| 2026-01-20 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,623,334 | ||
| 2026-01-06 | Borgeson Blake Director | Sale 10b5-1 | −220,000 | $4.36 | $959K | 6,649,863 |
| 2026-01-05 | Gibson Christopher Director | Conversion 10b5-1 | +60,000 | 973,839 | ||
| 2026-01-05 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $4.25 | $170K | 933,839 |
| 2026-01-05 | Gibson Christopher Director | Gift 10b5-1 | −20,000 | 913,839 | ||
| 2026-01-05 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −60,000 | 4,663,334 | ||
| 2026-01-02 | Dar Zavain Director | Grant or award | +3,571 | 142,329 | ||
| 2026-01-02 | Li Dean Y Director | Grant or award | +2,381 | 1,240,909 | ||
| 2025-12-29 | Taylor Ben R Chief Financial Officer | Sale 10b5-1 | −21,383 | $4.18 | $89K | 761,550 |
| 2025-12-22 | Khan Najat Chief R&D Commercial Officer | Sale 10b5-1 | −124,403 | $4.41 | $549K | 611,135 |
Page 5 of 9 · 179 trades